Skip to main content
Premium Trial:

Request an Annual Quote

Robert McBurney, Lorin Randall, Peter Dansky, Kip Miller, Nicolas Barthelemy, Laura Lauman, David Hoffmeister, Bernd Brust, Peter Leddy, Mark O’Donnell, John Cottingham, Paul Grossman, Joe Beery, Brian Pollock, Mark Smedley

Premium
TheraGenetics this week announced that it has appointed Robert McBurney to the newly created position of executive VP. In this position, McBurney will be responsible for leading TheraGenetics’ global business development and partnership strategy. Previously, McBurney was senior VP of research and development and chief scientific officer at BG Medicine
 

 
Nanosphere has appointed Lorin Randall to its board of directors. Randall formerly was chief financial officer at Eximias Pharmaceutical, and he was CFO of i-STAT, which is now owned by Abbott Laboratories, and he serves on the boards at several healthcare companies.
 

 
Invitrogen and Applied Biosystems have named the executives that will lead the four divisions of the merged company. The molecular biology systems division will be led by Peter Dansky, who currently serves as leader of ABI’s molecular and cell biology functional analysis division. It will include the workflows of both firms related to molecular biology, such as gene expression, genotyping, gene regulation, and proteomics.
 
The genetic systems division will be led by Kip Miller, who currently serves as leader of Invitrogen’s Biodiscovery division. It will include ABI’s capillary electrophoresis and SOLiD sequencing systems, as well as Invitrogen’s third-generation sequencing development program.
 
The cell systems division will be led by Nicolas Barthelemy, who currently heads Invitrogen’s cell systems division. It will include Invitrogen’s current cell systems operations and ABI’s Poros and Tropix business lines.
 
The mass spectrometry division will be led by Laura Lauman, who currently leads ABI’s proteomics and small molecule division, and will house ABI’s mass spec business.
 

In addition, David Hoffmeister, currently Invitrogen’s CFO, will assume the same position at the new company; Bernd Brust, head of invitrogen’s global sales and marketing, will head global commercial operations; Peter Leddy, head of Invitrogen’s human resources, will become head of global human resources; Mark O’Donnell, now head of ABI's global services and supply chain, will lead global operations and services; John Cottingham, general counsel for Invitrogen, will become chief legal officer; Paul Grossman, Invitrogen’s lead for strategy and corporate development, will assume the same title; Joe Beery will take on the same title he currently holds at Invitrogen, head of information technology; Brian Pollock, CSO of Invitrogen, will be head of global research and development; and Mark Smedley will continue as full-time integration leader and head of the Integration Management Office. He has been directing the integration efforts.

 

Filed under

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.